Cholangiocarcinoma

LEXINGTON, Mass., May 11, 2026 Partner Therapeutics, Inc. (PTx) announced that the U.S. Food and Drug Administration (FDA) has...

SILVER SPRING, Maryland, May 8, 2026 The U.S. Food and Drug Administration (FDA) has approved Bizengri (zenocutuzumab-zbco) for the...

LEXINGTON, Massachusetts, United States – May 6, 2026 Partner Therapeutics has announced that the U.S. Food and Drug Administration...

LEXINGTON, MASSACHUSETTS, USA, April 14, 2026 Partner Therapeutics, Inc. has announced the submission of a supplemental Biologics License Application...

WALTHAM, Mass., Feb. 2026 — Partner Therapeutics announced that zenocutuzumab-zbco, an investigational bispecific antibody therapy, has received U.S. FDA...

LEXINGTON, Mass., October 23, 2025– Partner Therapeutics, Inc. (PTx), a fully integrated biotechnology company, announced that the U.S. Food...